Hence, the identification of reliable prognostic biomarkers, such as DTWD2, has the potential to play a pivotal role in predicting treatment outcomes and guiding personalized therapeutic strategies for COAD patients [16]. The gene discussed is DTWD2; the disease is colon adenocarcinoma.